Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.40 USD
Change Today -0.0055 / -1.34%
Volume 157.7K
As of 8:04 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

provectus biopharmaceutica-a (PVCT) Snapshot

Open
$0.42
Previous Close
$0.41
Day High
$0.42
Day Low
$0.40
52 Week High
09/15/14 - $1.20
52 Week Low
08/24/15 - $0.32
Market Cap
82.8M
Average Volume 10 Days
353.2K
EPS TTM
$-0.05
Shares Outstanding
204.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PROVECTUS BIOPHARMACEUTICA-A (PVCT)

Related News

No related news articles were found.

provectus biopharmaceutica-a (PVCT) Related Businessweek News

No Related Businessweek News Found

provectus biopharmaceutica-a (PVCT) Details

Provectus Biopharmaceuticals, Inc., a biopharmaceutical company, engages in developing ethical pharmaceuticals for oncology and dermatology indications. Its product line includes PV-10, which is in Phase III study for metastatic melanoma; completed a Phase I study for breast cancer; and is in Phase I protocol expansion for liver metastasis, as well as initiated a Phase I feasibility study to detect immune cell infiltration into melanomas. The company is also developing PH-10 that is in Phase IIc randomized study for the treatment of psoriasis; and has completed Phase II study for the treatment of atopic dermatitis. In addition, it develops PH-10 for the treatment of actinic keratosis and severe acne vulgaris. Further, the company is developing over-the-counter pharmaceuticals, including GloveAid, a hand cream with antiperspirant and antibacterial properties; Pure-ific line of products to prevent the spread of germs on skin; and Pure-Stick and Pure N Clear acne products. Additionally, it develops medical device technologies for markets comprising cosmetic treatments, such as reduction of wrinkles and elimination of spider veins, and other cosmetic blemishes; and therapeutic uses, including photoactivation of PH-10, other prescription drugs, and non-surgical destruction of various skin cancers. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.

4 Employees
Last Reported Date: 08/6/15
Founded in 2002

provectus biopharmaceutica-a (PVCT) Top Compensated Officers

Chairman, Chief Executive Officer, Chief Exec...
Total Annual Compensation: $500.0K
President, Director, President of Xantech and...
Total Annual Compensation: $500.0K
Chief Operating Officer, Chief Financial Offi...
Total Annual Compensation: $500.0K
Chief Technology Officer and Executive Vice P...
Total Annual Compensation: $500.0K
Compensation as of Fiscal Year 2014.

provectus biopharmaceutica-a (PVCT) Key Developments

Provectus Biopharmaceuticals, Inc. to Report Q2, 2015 Results on Aug 06, 2015

Provectus Biopharmaceuticals, Inc. announced that they will report Q2, 2015 results at 1:00 PM, GMT Standard Time on Aug 06, 2015

Provectus Biopharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 06, 2015

Provectus Biopharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 06, 2015

Provectus Biopharmaceuticals Mulls Acquisitions

Provectus Biopharmaceuticals, Inc. (AMEX:PVCT) filed a shelf registration in the amount of $100 million and intends to use the proceeds for the expansion of our business through internal growth or acquisitions.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PVCT:US $0.40 USD -0.0055

PVCT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PVCT.
View Industry Companies
 

Industry Analysis

PVCT

Industry Average

Valuation PVCT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROVECTUS BIOPHARMACEUTICA-A, please visit www.pvct.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.